This clinical trial shows that KIM-1 may be helpful in the long-term surveillance of patients treated for chronic diseases where nephroprotection is crucial, such as hypertension, CKD, and diabetes mellitus. This evidence concerns the gene HAVCR1 and diabetes mellitus.